New-Onset Vitiligo Following Etanercept for Ankylosing Spondylitis
Main Article Content
Keywords
vitiligo, etanercept, TNF-alpha inhibitors, ankylosing spondylitis, immune-mediated skin disease
Abstract
Tumor Necrosis Factor-alpha (TNF-a) inhibitors, are used widely to treat a variety of chronic inflammatory conditions such as ankylosing spondylitis, Crohn’s disease, rheumatoid arthritis, and psoriasis. Recently, there has been an increase in the number of reports of immune-mediated skin diseases, such as lichen planus, psoriasis, granuloma annulare, following the initiation of TNF-a inhibitors. We present a patient with ankylosing spondylitis previously treated with adalimumab who developed vitiligo shortly after switching to etanercept to achieve better control of his joint disease.
References
Ismail WA, Al-Enzy SA, Alsurayei SA, Ismail AE. Vitiligo in a patient receiving infliximab for refractory ulcerative colitis. Arab J Gastroenterol. 2011;12(2):109-111. doi:10.1016/j.ajg.2011.03.001.
Carvalho CLDB, Ortigosa LCM. Segmental vitiligo after infliximab use for rheumatoid arthritis – a case report. An Bras Dermatol. 2014;89(1). doi: 10.1590/abd1806-4841.20142887
Toussirot E, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview. RMD Open. 2016;2(2):1-12. doi:10.1136/rmdopen-2015-000239.
Simon JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Case Rep Dermatol. 2008;216:234-235. Doi: 10.1159/000112932
Bae JM, Kim M, Lee HH, et al. Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study. J Invest Dermatol. 2018;138(4):768-774. doi:10.1016/j.jid.2017.11.012.